Publication Name	World Journal of Hepatology
Manuscript ID	2977
Country	China

Received	2013-03-29 12:30
Peer-Review Started	2013-03-29 14:51
To Make the First Decision	2013-04-16 09:16
Return for Revision	2013-04-18 19:38
Revised	2013-04-26 13:12
Second Decision	2013-06-08 14:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-06-10 04:11
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-06-21 13:21
Typeset the Manuscript	2013-07-19 17:18
Publish the Manuscript Online	2013-07-25 09:10

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Bo Zhai and Xue-Ying Sun
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Scientific Foundation of China 30973474 National Natural Scientific Foundation of China 81272467
Corresponding Author	Xue-Ying Sun, MD, PhD, Professor, The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China. kevsun88@hotmail.com
Key Words	Hepatocellular carcinoma; Sorafenib; Drug resistance; Cellular signaling pathway; Clinical trials
Core Tip	The primary resistance of hepatocellular carcinoma (HCC) to sorafenib is due to genetic heterogeneity. Thus, seeking predictive biomarkers and combining sorafenib with other anticancer agents for HCC have been launched with varying degrees of success. Sorafenib inhibits several kinase targets but it can also simultaneously or sequentially activate the addiction switches and compensatory pathways, inducing acquired resistance. Some other molecular targeted drugs have been used as second-line treatment for advanced HCC after the failure of sorafenib therapy. Further investigation on the crosstalk and relationship of associated pathways will better our understanding of the mechanisms accounting for sorafenib resistance in HCC.
Publish Date	2013-07-25 09:10
Citation	Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5(7): 345-352
URL	http://www.wjgnet.com/1948-5182/full/v5/i7/345.htm
DOI	http://dx.doi.org/10.4254/wjh.v5.i7.345

Full Article (PDF)	WJH-5-345.pdf
Manuscript File	2977-Review.docx
Answering Reviewers	2977-Answering reviewers.docx
Copyright License Agreement	2977-Copyright assignment.PDF
Peer-review Report	2977-Peer review(s).pdf
Scientific Editor Work List	2977-Scientific editor work list.doc